Collagen type I synthesis and extracellular matrix remodeling pathway

The Collagen type I synthesis and extracellular matrix (ECM) remodeling pathway is a coordinated biological process involving the production, maturation, and degradation of structural proteins that maintain tissue integrity (Verrecchia & Mauviel, 2007, PubMed). Collagen type I, the primary component of the ECM in skin, bone, and tendons, is synthesized as procollagen and subsequently processed by enzymes like lysyl oxidase (LOX) to form stable fibrils (Karsdal et al., 2017, Advanced Drug Delivery Reviews). This pathway is primarily regulated by Transforming Growth Factor-beta (TGF-β) signaling, which stimulates collagen gene expression while inhibiting degradative enzymes like matrix metalloproteinases (MMPs) (Biernacka et al., 2011, Growth Factors). Pathological activation of this pathway leads to excessive ECM deposition, resulting in fibrosis of the lungs, liver, and kidneys, and contributes to the stiffening of the tumor microenvironment in cancer (Cox & Erler, 2011, Disease Models & Mechanisms). Therapeutic interventions such as Pirfenidone and Nintedanib aim to modulate this pathway by reducing collagen production or inhibiting upstream growth factor receptors to treat conditions like idiopathic pulmonary fibrosis (Richeldi et al., 2014, NEJM). Additionally, targeting the cross-linking enzyme LOX or its isoforms has been explored to reduce tissue stiffness and limit cancer progression (Barker et al., 2012, Nature Reviews Cancer). Monitoring this pathway often involves measuring circulating collagen fragments, which serve as biomarkers for disease activity and treatment response (Nielsen et al., 2019, Journal of Hepatology).

Other names

Extracellular matrix remodeling pathwayCollagen type I production pathwayFibrotic signaling cascade

Inhibition of TGF-beta signaling, inhibition of collagen cross-linking, and modulation of matrix metalloproteinase activity.